# A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

> **NCT01724814** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 86 (actual)

## Conditions studied

- Healthy
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** HM12460A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01724814
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-20
- **Primary completion:** 2014-07-01
- **Final completion:** 2014-07-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724814, "A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01724814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*